Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

Technology appraisal guidance
Reference number: TA335
Published: 25 March 2015

Acute coronary syndrome - rivaroxaban [ID532]: final appraisal determination document

Acute coronary syndrome - rivaroxaban [ID532]: final appraisal determination document

Acute coronary syndrome - rivaroxaban [ID532]: final appraisal determination document
23 January 2015
(420.5 Kb 2 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 19 January 2015